HC Wainwright Reaffirms Buy Rating for Zevra Therapeutics
Analyst Brandon Folkes reaffirms a buy rating with a $26 target for Zevra Therapeutics, a 99.39% upside from the current price.
Key Points
- HC Wainwright's Brandon Folkes reiterated a buy rating for Zevra Therapeutics with a $26 price target on June 23, 2026.
- HC Wainwright's $26 price target implies 99.39% upside from Zevra Therapeutics, Inc.'s ($ZVRA) current $13.04 share price.
- Zevra Therapeutics trades on NasdaqGS at around $12.86, with a market cap of approximately $748 million and a P/E ratio of 6.29.
- Other analysts like Maxim Group and BTIG also maintain buy ratings, targeting prices as high as $35.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating for Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) with a price target of $26. Analyst Brandon Folkes made this reaffirmation on June 23, 2026. With shares trading near $12.86 on Tuesday, this target suggests significant potential upside.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Zevra Therapeutics, Inc. Stock Up 12.8%
Shares of NasdaqGS:ZVRA traded around $12.86 on Tuesday. Zevra Therapeutics boasts a market cap of approximately $748 million and has a P/E ratio of 6.29. The stock's beta is 0.894, indicating lower volatility compared to the market. Over the last 52 weeks, the stock has ranged from $7.16 to $14.27. Its 50-day moving average is $10.95, while the 200-day moving average is $9.59. Zevra's financial health is strong, with a current ratio of 4.89 and a quick ratio of 4.74, alongside a debt-to-equity ratio of 0.557.
$ZVRA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Zevra Therapeutics reported revenue of $122.3 million, reflecting a growth rate of 77.5%. The company has a net margin of 101.58% and a return on equity of 100.65%. Earnings per share stand at $2.01. The next earnings release is expected on August 11, 2026.
Insider Buying and Selling at Zevra Therapeutics, Inc.
Several insiders at Zevra Therapeutics, including Tamara Favorito, Douglas Calder, Corey Michael Watton, Thomas Anderson, Alvin Shih, and Alicia Secor, each bought 30,000 shares on June 4, 2026. These transactions were not part of any planned trading program.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating for Zevra Therapeutics, setting a $26 price target. Other firms like Canaccord Genuity and Maxim Group also maintained buy ratings, with targets of $29 and $35, respectively. The consensus among analysts is a strong buy, with a mean target price of $27.89 based on 9 analyst opinions.
About Zevra Therapeutics
Zevra Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focusing on rare diseases. The company uses its Ligand Activated Technology platform to develop treatments. Its lead products include KP1077 for idiopathic hypersomnia and narcolepsy, and Celiprolol for vascular Ehlers Danlos syndrome. Zevra also offers AZSTARYS for ADHD, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C. Led by CEO Neil F. McFarlane, Zevra was formerly known as KemPharm, Inc.
Bottom Line
HC Wainwright's reaffirmation of a buy rating for Zevra Therapeutics underscores confidence in the company's potential. With shares trading at $12.86, the $26 price target implies a notable upside. As a commercial-stage biotech firm, Zevra's focus on rare diseases and strong financials make it a company to watch. Remember, analyst ratings are based on past performance and expectations, and may not reflect future market conditions.
Get Zevra Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZVRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.